RxDoctor Payments Data

Bruce Bradley

Cardiovascular Disease · Lexington, KYNPI 1376850099

Payments from drug & device makers

$3,988in general payments, 2019–2025

Across 179 payments — averaging $22.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$957
  • Johnson & Johnson$579
  • Pfizer$526
  • Novartis$383
  • Merck$260
  • AstraZeneca$186
  • plus $1K from 18 others

What the payments were for

  • Travel & lodging$40610%
  • Food & beverage$3,56789%
  • Education$160%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,988 in reported general payments places this provider in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

See all cardiovascular disease providers in Kentucky

Medicare billing

Part B allowed, 2024
$298,766
Medicare patients
1,554
Services billed
4,103

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban574$619,306
XareltoRivaroxaban255$300,210
EntrestoSacubitril/Valsartan195$232,014
CamzyosMavacamten12$101,453
Repatha SureclickEvolocumab93$81,401
JardianceEmpagliflozin68$77,806
BrilintaTicagrelor11$10,496
Metoprolol Succinate510$6,865
Flecainide Acetate121$5,063
Ranolazine ErRanolazine26$3,317
Atorvastatin Calcium258$2,611
Losartan Potassium285$2,338
Dofetilide26$2,323
Amiodarone Hcl103$2,281
Midodrine Hcl23$2,214

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$526$619,306574 claims
Johnson & JohnsonXarelto$579$300,210255 claims
NovartisEntresto$383$232,014195 claims
E.r. Squibb & Sons, L.L.C.Camzyos$43$101,45312 claims
Boehringer IngelheimJardiance$139$77,80668 claims
AstraZenecaBrilinta$186$10,49611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 258 cardiovascular disease providers in Kentucky.

Other cardiovascular disease in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →